(Total Views: 145)
Posted On: 11/01/2023 4:23:14 PM
Post# of 231
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany. Vaczy’s presentation is slated to begin at 4:45 p.m UTC on Tuesday, Nov. 7, 2023. Several members of Genprex’s executive leadership team will be in attendance at BIO-Europe 2023. Those interested in meeting Genprex management during the event should request a meeting through the conference portal or reach out to investor relations at investors@genprex.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany. Vaczy’s presentation is slated to begin at 4:45 p.m UTC on Tuesday, Nov. 7, 2023. Several members of Genprex’s executive leadership team will be in attendance at BIO-Europe 2023. Those interested in meeting Genprex management during the event should request a meeting through the conference portal or reach out to investor relations at investors@genprex.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
